Bifogade filer
Prolight Diagnostics etablerar Clinical Advisory Board
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Nordic SME Sweden |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Prolight Diagnostics (”Prolight”) är glada över att kunna tillkännage bildandet av sitt Clinical Advisory Board bestående av sex framstående, internationellt erkända experter inom kardiologi, akutmedicin och klinisk patologi. Expertgruppen kommer att vara avgörande för den fortsatta produktutvecklingen och de kliniska studierna av Prolights unika digitala patientnära analyssystem, även benämnt point-of-care (POC)-system för analys av olika biomarkörer. Prolights lanseringsprodukt blir mätning av biomarkören troponin för att kunna upptäcka och utesluta hjärtinfarkt.
"Vi är exceptionellt glada och hedrade över att ha dessa globalt erkända kliniska experter i vårt Clinical Advisory Board. Deras intresse för vårt egenutvecklade, digitala POC-system är uppmuntrande och vi hoppas få användbara insikter från dem när vi går mot klinisk validering och kommersialisering av Psyros™ POC-system”, säger Ulf Bladin, vd för Prolight.
Prolights Clinical Advisory Board består av följande internationellt erkända experter inom kardiologi, akutmedicin och klinisk patologi.
MD Richard Body, Professor of Emergency Medicine at the University of Manchester and Honorary Consultant in Emergency Medicine and Group Director of Research & Innovation at Manchester University NHS Foundation Trust, sits on the IFCC point-of-care committee and has a high interest in developing the best strategy of managing patients with myocardial infarction including the use of point-of-care biomarkers such as high-sensitive troponin.
MD Paul Collinson, Professor of Cardiovascular Biomarkers at St. George’s Medical School, and previously consultant chemical pathologist at St. George's University Hospital of London, where he was responsible for the Point of Care team. He has published over 300 papers and review articles and is an active member of Committee on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry (IFCC) where he was lead author on the recent IFCC recommendations on Cardiac Markers by Point of Care testing.
MD Thomas Kaier is an interventional cardiologist at St Thomas’ Hospital with a research background investigating the role of novel biomarkers in ischaemic heart disease on a protein basis. He holds a Master of Business Administration and completed a PhD in Cardiovascular Medical Research at King’s College London.
MD Michael Marber, Professor of Cardiology at King’s College London, has a clinical interest in acute cardiac care and translational research focusing on myocardial ischaemia with over 400 publications on the subject.
MD Nicholas Mills, Professor of Cardiology at the University of Edinburgh, is a Consultant Cardiologist at the Royal Infirmary of Edinburgh and British Heart Foundation Chair of Cardiology. His research aims to understand the mechanisms of myocardial injury in patients with heart disease, and to identify novel approaches to improve risk stratification and clinical outcomes in these patients. He is also an active member of Committee on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry (IFCC).
MD Raphael Twerenbold, MD Raphael Twerenbold, Professor of Clinical Cardiology and interventional cardiologist at the University Medical Centre Hamburg Eppendorf, Hamburg, Germany, with a focus on cardiovascular biomarkers and genetics. He is actively exploring the clinical utility of circulating biomarkers in acute and chronic cardiovascular care and author of several influential articles on the clinical use of high-sensitive cardiac troponin in patients with suspected myocardial infarction.